www.immunobiochem.com
Innovation Type:
Therapeutics
Cancer Type:
Heme
Funding Stage:
Pre-seed
Fund:
Prospects
Novel degrader-antibody conjugate (DAC) therapeutics combining the robustness of ADCs with the catalytic power of targeted protein degraders for the treatment of resistant leukemia